College of Laboratory Medicine, Jilin Medical University, Jilin, 132013, China.
Department of Pharmacological and Pharmaceutical Science, College of Pharmacy, University of Houston, Houston, TX, 77030, USA.
Tissue Cell. 2021 Oct;72:101546. doi: 10.1016/j.tice.2021.101546. Epub 2021 Apr 18.
Anoctamin 7 (ANO7) is a member of the transmembrane protein TMEM16 family. It has a conservative topology similar to other members in this family, such as the typical eight-transmembrane domain, but it also has unique features. Although the ion channel role of ANO7 has been well accepted, evolutionary analyses and relevant studies suggest that ANO7 may be a multi-facet protein in function. Studies have shown that ANO7 may also function as a scramblase. ANO7 is highly expressed in prostate cancer as well as normal prostate tissues. A considerable amount of evidence has confirmed that ANO7 is associated with human physiology and pathology, particularly with the development of prostate cancer, which makes ANO7 a good candidate as a diagnostic and prognostic biomarker. In addition, ANO7 may be a potential target for prostate cancer immunotherapy. Antibody-based or T cell-mediated immunotherapies against prostate cancer by targeting ANO7 have been highly anticipated. ANO7 may also correlate with several other types of cancers or diseases, where further studies are warranted.
ANO7（Anoctamin 7）是跨膜蛋白 TMEM16 家族的成员。它具有与该家族其他成员相似的保守拓扑结构，如典型的八跨膜域，但也具有独特的特征。尽管 ANO7 的离子通道作用已得到广泛认可，但进化分析和相关研究表明，ANO7 在功能上可能是一种多方面的蛋白质。研究表明，ANO7 也可能作为一种翻转酶发挥作用。ANO7 在前列腺癌以及正常前列腺组织中高度表达。大量证据已经证实，ANO7 与人体生理学和病理学，特别是前列腺癌的发生发展有关，这使得 ANO7 成为一种有前途的诊断和预后生物标志物。此外，ANO7 可能是前列腺癌免疫治疗的潜在靶点。针对 ANO7 的抗体或 T 细胞介导的免疫疗法治疗前列腺癌备受期待。ANO7 也可能与其他几种类型的癌症或疾病相关，进一步的研究是必要的。
